On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized
You may also be interested in...
A New Front: India’s Natco Gets State-level Nod To Sell Copies Of BMS’ Sprycel
Natco has gained approval from a state-level agency rather than India’s DCGI, opening up a new front in the battle between Indian companies and MNCs.
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs